百利天恒：T-Bren(HER2 ADC)用于在HER2阳性局部晚期或转移性胃或胃食管结合部腺癌III期临床试验完成首例受试者入组

Core Viewpoint - The company, BaiLi Tianheng (688506.SH), has announced the completion of the first patient enrollment in a Phase III clinical trial for its innovative biopharmaceutical, T-Bren (HER2 ADC), targeting HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after first-line anti-HER2 treatment failure [1] Group 1 - T-Bren (BL-M07D1) is a targeted HER2 innovative ADC with best-in-class potential, demonstrating significant anti-tumor efficacy in clinical trials [1] - The Phase III clinical trial for T-Bren has recently entered the first patient enrollment stage, focusing on patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma [1] Group 2 - Currently, T-Bren is involved in 13 clinical trials both domestically and internationally, including 4 Phase III, 1 Phase II/III, 2 Phase II, 3 Phase I/II, and 3 Phase I trials [1] - The clinical trials cover various indications, including first-line and second-line HER2-positive breast cancer, postoperative adjuvant therapy for HER2-positive breast cancer, neoadjuvant therapy for HER2-positive breast cancer, HER2 low-expressing breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, as well as lung cancer, gastrointestinal tumors, urological tumors, and gynecological tumors [1]